DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: 1. Atopic Dermatitis (AD): Moderate-to-severe AD in patients ?6 months when topical therapies inadequate 2. Asthma: Add-on maintenance for moderate-to-severe asthma ?6 years (eosinophilic phenotype or steroid-dependent) 3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Add-on maintenance ?12 years 4. Eosinophilic Esophagitis (EoE): Treatment ?1 year, ?15 kg 5. Prurigo Nodularis (PN): Adult treatment 6. COPD: Add-on maintenance with eosinophilic phenotype 7. Chronic Spontaneous Urticaria (CSU): ?12 years despite H1 antihistamine 8. Bullous Pemphigoid (BP): Adult treatment

Interleukin inhibitors; Monoclonal antibodies

Bioavailability: ~64% (subcutaneous) Peak concentration: 3-7 days Half-life: 4-5 weeks Metabolism: Degraded to small peptides/amino acids via catabolic pathways

Known hypersensitivity to dupilumab or any excipients

IgG crosses placenta; fetal exposure expected. Animal studies (10× MRHD): No adverse developmental effects.

No data on presence in human milk.

AD: Injection site reactions (10%), conjunctivitis (10%), blepharitis (5%), oral herpes (4%) Asthma: Injection site reactions (14-18%), oropharyngeal pain (2%) CRSwNP: Injection site reactions (6%), arthralgia (3%) EoE: Injection site reactions (38%), upper respiratory infections (18%) PN: Nasopharyngitis (5%), conjunctivitis (4%) COPD: Viral infection (14%), headache (8%) CSU: Injection site reactions (10%) BP: Arthralgia (9%), conjunctivitis (8%)

Adults: 1. AD: 600 mg initial, then 300 mg Q2W 2. Asthma: 400-600 mg initial, then 200-300 mg Q2W 3. CRSwNP: 300 mg Q2W 4. EoE (?40 kg): 300 mg QW 5. PN: 600 mg initial, then 300 mg Q2W 6. COPD: 300 mg Q2W 7. CSU: 600 mg initial, then 300 mg Q2W 8. BP: 600 mg initial, then 300 mg Q2W (with tapering oral corticosteroids)

AD: ?6 months; Asthma: ?6 years; CRSwNP/CSU: ?12 years; EoE: ?1 year, ?15 kg. Not established for pediatric PN, COPD, BP.

No dosage adjustments required (degraded via catabolic pathways, not renally eliminated)

No dosage adjustments required (degraded via catabolic pathways, not hepatically eliminated)

Storage Before Use: Refrigerate 2-8°C in original carton (protect from light). Do not freeze or shake. Storage After Removal from Refrigerator: Allow to reach room temperature: 30 minutes (200 mg) or 45 minutes (300 mg). Use within 14 days after refrigerator removal.